William J. Hogan

Hematology | Oncology | Hematology Oncology

200 1st St Sw
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 411 publications

Clinics and Clicks: Optimizing Hematology Care Delivery and Workflows in the Digital Era.

Clinics and Clicks: Optimizing Hematology Care Delivery and Workflows in the Digital Era.

Journal: JCO oncology practice

Published: August 07, 2026

Umbilical Cord Blood Donor Outcomes in BMTCTN1702.

Umbilical Cord Blood Donor Outcomes in BMTCTN1702.

Journal: Blood advances

Published: August 03, 2026

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

Journal: medRxiv : the preprint server for health sciences

Published: July 29, 2026

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

Journal: American journal of hematology

Published: July 11, 2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

Journal: American journal of hematology

Published: May 29, 2026

Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.

Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.

Journal: Blood cancer journal

Published: May 27, 2026

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Journal: Blood immunology & cellular therapy

Published: May 15, 2026

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

Journal: American journal of hematology

Published: May 13, 2026

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

Journal: American journal of hematology

Published: May 12, 2026

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Journal: Blood advances

Published: May 12, 2026

Hematopoietic Cell Transplant Access and Patient Diversity.

Hematopoietic Cell Transplant Access and Patient Diversity.

Journal: JAMA network open

Published: May 05, 2026

Exercise Duration during a Brief Step Test Independently Predicts Outcomes after Hematopoietic Cell Transplantation.

Exercise Duration during a Brief Step Test Independently Predicts Outcomes after Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: May 03, 2026

Showing 1-12 of 411

Last Updated: 09/26/2026